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Background—Corticosteroid use is widespread in recurrent pericarditis, even if rarely indicated, and high doses (eg,
prednisone 1.0 to 1.5 mg · kg1 · d1) are generally recommended, although only weak evidence supports their use with
possible severe side effects. The aim of this work was to compare side effects, recurrences and other complications, and
hospitalizations of a low- versus high-dose regimen of prednisone for recurrent pericarditis.
Methods and Results—A retrospective review of all cases of recurrent pericarditis treated with corticosteroids according
to different regimens from January 1996 to June 2004 was performed in 2 Italian referral centers. One hundred patients
with recurrent pericarditis (mean age, 50.115.8 years; 57 females) were included in the study; 49 patients (mean age,
47.516.0; 25 females) were treated with low doses of prednisone (0.2 to 0.5 mg · kg1 · d1), and 51 patients (mean
age, 52.615.3; 32 females) were treated with prednisone 1.0 mg · kg1 · d1. Baseline demographic and clinical
characteristics were well balanced across the groups. Each initial dose was maintained for 4 weeks and then slowly
tapered. After adjustment for potential confounders (age, female gender, nonidiopathic origin), only high doses of
prednisone were associated with severe side effects, recurrences, and hospitalizations (hazard ratio, 3.61; 95%
confidence interval, 1.96 to 6.63; P0.001).
Conclusions—Use of higher doses of prednisone (1.0 mg · kg1 · d1) for recurrent pericarditis is associated with more side
effects, recurrences, and hospitalizations. Lower doses of prednisone should be considered when corticosteroids are
needed to treat pericarditis. (Circulation. 2008;118:667-671.)
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Even if rarely indicated, recurrent pericarditis often istreated with corticosteroids in clinical practice. Cortico-
steroids can induce a quick response with symptom control
and initial remission. Despite the fact that guidelines and
reviews1–9 recommend limiting the use of corticosteroids in
pericarditis, the use of these drugs is widespread. Only 1
retrospective study supports their use.10 Following this study,
reviews and current European guidelines on the management
of pericardial diseases3,5–8 have recommended the use of high
doses of prednisone (1.0 to 1.5 mg · kg1 · d1) for 1 month
in patients with recurrent pericarditis when corticosteroids are
considered.
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Unfortunately, the treatment often is quickly tapered be-
cause of the fear of possible side effects, and relapses and
severe side effects related to the need of prolonged treatments
with steroids are common. Thus, one of the most troublesome
issues in pericardial diseases is how to manage a patient with
recurrent pericarditis and corticosteroid dependence.1–10 When
high doses are considered, side effects are not uncommon
and may be cause of early withdrawal of the drugs. Low to
moderate doses of corticosteroids (ie, prednisone 0.2 to 0.5
mg · kg1 · d1) are commonly prescribed to treat serositis in
patients with rheumatologic conditions. Use of these lower
doses may be a way to minimize side effects.
The aim of the present study was to retrospectively
compare the side effects, recurrences and other complica-
tions, and hospitalizations of 2 different therapeutic regimens
of corticosteroids for recurrent pericarditis: high doses (ie,
prednisone 1.0 mg · kg1 · d1) and low doses (ie, prednisone
0.2 to 0.5 mg · kg1 · d1).
Methods
Study Design and Subjects
Data prospectively recorded from all clinical cases of recurrent
pericarditis treated with corticosteroids from January 1996 to June
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2004 in 2 Italian referral centers for the treatment of pericarditis
(center A, Maria Vittoria Hospital, Torino; center B, Niguarda
Hospital, Milano) were retrospectively reviewed. Inclusion criteria
were definite diagnosis of recurrent pericarditis (idiopathic, viral,
and autoimmune causes, including postpericardiotomy syndromes,
and connective tissue diseases) and age18 years. Exclusion criteria
were tuberculous and neoplastic or purulent origins. The clinical
diagnosis of recurrence was based at least on recurrent chest pain and
1 of the following signs: fever, pericardial friction rub, ECG
changes, or echocardiographic evidence of new or worsening peri-
cardial effusion. Elevation of C-reactive protein or increased eryth-
rocyte sedimentation rate was required in all cases to confirm the
diagnosis of recurrence.11–15
Treatment Plan
In both institutions, corticosteroid therapy was prescribed only in
patients with aspirin and nonsteroidal antiinflammatory drug
(NSAID) contraindications, intolerance, or failure. The corticoste-
roid of choice was prednisone. Two different doses were prescribed
for 4 weeks and then gradually tapered: high doses (1.0 mg · kg1 ·
d1)10 in center A or low doses (0.2 to 0.5 mg · kg1 · d1) in center
B, according to local treatment protocols. Tapering was similar in the
2 regimens; a detailed description of the tapering according to
prednisone daily doses is reported in Table 1. Each decrement was
attempted in the absence of symptoms and when C-reactive protein
levels were normal. If symptoms recurred during tapering, every
effort was made not to increase the dose of or to reinstitute
corticosteroids and to control symptoms by beginning or increasing
the doses of aspirin or NSAID. Because these are tertiary referral
centers, most patients were referred after failure of previous thera-
pies, including steroids, and in these cases, the dose and type of
corticosteroid were modified according to the described protocol.
During tapering, aspirin or an NSAID was added whenever possible
using a gastroduodenal prophylaxis with a proton-pump inhibitor as
previously published,8,11 and colchicine (0.5 to 1.0 mg/d) was added
if tolerated. After routine care of recurrent pericarditis in the 2
centers, all patients had a clinical and echocardiographic follow-up at
least up to 18 months after the initial diagnosis of recurrence.
Outcomes
The primary outcome was the rate of severe side effects. A severe
adverse event was considered an untoward event that was fatal or
life-threatening, required hospitalization, or was significantly or
permanently disabling or medically significant (may jeopardize the
patient and may require medical or surgical intervention to prevent
an adverse outcome). Secondary outcomes of the study were the
recurrence rate, cardiac tamponade, constrictive pericarditis, minor
side effects, and hospitalization related to recurrent pericarditis.
Patients were considered to be in remission when they were
symptom free with no clinical, ECG, or echocardiographic signs and
with normalization of C-reactive protein.11–14
Statistical Analysis
Data are expressed as meanSD. Comparison between patient
groups was performed with an unpaired t test for continuous
variables; Fisher exact test was used for proportions between groups.
A value of P0.05 was considered statistically significant.
Time-to-event distributions were estimated with the Kaplan-Meier
method and compared by use of the log-rank test. The Cox
proportional-hazards model was used to adjust for age and other
potential confounders at baseline, including female gender and
nonidiopathic origin. All analyses were performed with the SPSS
13.0 software package (SPSS Inc, Chicago, Ill).
The authors had full access to and take full responsibility for the
integrity of the data. All authors have read and agree to the
manuscript as written.
Results
One hundred consecutive patients with recurrent pericarditis
(mean age, 50.115.8 years; 57 women) who were treated
with corticosteroids from January 1996 to June 2004 were
included in this retrospective study. Information on vital
status and clinical follow-up data were available in all patients
for a mean follow-up of 55.8 months (range, 18 to 96 months).
Forty-nine patients (mean age, 47.516.0; 25 women) were
treated with lower doses of prednisone (0.2 to 0.5 mg · kg1 · d1;
group 1), and 51 patients (mean age, 52.615.3; 32 females)
were treated with prednisone 1 mg · kg1 · d1; group 2).
Baseline demographic and clinical characteristics were well
balanced across the groups (Table 2).
Outcomes
Patients treated with high doses of prednisone (group 2) had
a higher rate of severe side effects compared with patients
treated with lower doses (group 1) (23.5% versus 2.0%,
respectively; P0.002).
Recorded severe side effects included vertebral collapse in
4 cases, severe osteoporosis requiring medical intervention in
4 cases, and severe cushingoid syndrome in 5 other cases.
A higher recurrence rate was recorded in group 2 than in
group 1 (64.7% versus 32.6%, respectively; P0.002), as
well as a higher frequency of minor side effects (including
abdominal pain, dyspepsia, sodium-water retention, hyper-
glycemia, and skeletal myopathy) and disease-related hospi-
talizations (31.4% versus 8.2%; P0.005). A detailed sum-
mary of the follow-up data is reported in Table 3.
After adjustment for potential confounders (age, female
gender, nonidiopathic origin), only high doses of prednisone
were associated with severe side effects, recurrences, and
Table 1. Tapering Regimen of Prednisone in
Recurrent Pericarditis
Prednisone Daily Dose, mg Tapering
50 10 mg/d every 1 to 2 wk
50–25 5–10 mg/d every 1 to 2 wk
25–15 2.5 mg/d every 2 to 4 wk
15 1.25 to 2.5 mg/d every 2 to 6 wk
Every decrease in prednisone dose should be done only if the patient is
asymptomatic and C-reactive protein is normal, particularly for doses 25 mg/d.
Table 2. Baseline Clinical Characteristics of the
Studied Population
Feature
Group 1,
Low Dose
(n49)
Group 2,
High Dose
(n51) P
Age, y 47.516.0 52.615.3 0.106
Women, n (%) 25 (51.0) 32 (62.7) 0.313
Pericardial effusion, n (%) 14 (28.6) 17 (33.3) 0.669
Cardiac tamponade, n (%) 3 (6.1) 1 (2.0) 0.357
Idiopathic origin, n (%) 35 (71.4) 38 (74.5) 0.823
Autoimmune origins, n (%)* 14 (28.6) 13 (25.5) 0.823
Mean recurrences, n 4.96.9 5.13.2 0.773
Values are meanSD when appropriate. Prednisone low dose was 0.2 to 0.5
mg  kg1  d1 and high dose was 1.0 to 1.5 mg  kg1  d1. The mean
number of recurrences is reported at the beginning of the observation.
*Autoimmune causes include connective tissue diseases and postpericar-
diotomy syndromes.
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hospitalizations (hazard ratio, 3.61; 95% confidence interval,
1.96 to 6.63; P0.001; Table 4).
Patients treated with prednisone 1 mg · kg1 · d1 had a
lower event-free survival compared with those treated with
lower doses (the Figure). Assessed adverse events included
severe side effects, recurrences, cardiac tamponade, and
constrictive pericarditis.
Discussion
Major Findings
The present study challenges the current practice of using
high doses of prednisone or other corticosteroids to treat
pericarditis. Corticosteroid use should be restricted in peri-
carditis, but when indicated, high doses are recommended in
reviews and the European guidelines on the management of
pericardial diseases.5–8 Although the practice of using high
doses of prednisone is not uncommon and was the established
regimen for decades, the evidence supporting this indication in
recurrent pericarditis is weak, based only on a small retrospec-
tive study.10 In this study, 12 patients with recurrent pericarditis
unrelated to any systemic disease were treated with a 3-month
course of high-dose prednisone (1.0 to 1.5 mg · kg1 · d1) for 1
month and subsequent gradual tapering. When prednisone ta-
pering was started, all patients received a 5-month course of
aspirin (1.6 g/d until steroid withdrawal and then 0.8 g/d).
During a mean follow-up of 42 months, treatment with high
doses of prednisone resulted in stable remission in all except
1 patient. In this study, the efficacy of prolonged treatment
with aspirin cannot be excluded as an explanation of the
overall good remission rate. Moreover, 3 patients (25%) had
severe steroid-related adverse effects; 2 of them were treated
with other immunosuppressive treatments (1 with azathio-
prine, 1 with cyclophosphamide).
Lower doses of steroids are commonly used to treat
serositis in patients with chronic autoimmune diseases such
as systemic lupus erythematosus and Sjögren syndrome.15,16
These therapeutic schemes also might be reasonably applied
in recurrent pericarditis.
In fact, corticosteroid toxicity is related to both the average
dose and cumulative duration of treatment. For example, in a
study on rheumatoid arthritis, the average daily prednisone
dose was the strongest predictor of serious side effects related
to steroid therapy (odds ratio, 4.5 for prednisone 5 to 10 mg
but 32.3 for prednisone 10 to 15 mg). The correlation with
side effects was either dose and time dependent even after
correction for the severity of the disease.17
Guidelines recommend osteoporosis prevention when
these drugs are used, an issue often forgotten in clinical
practice. Supplementation with calcium and vitamin D (1500
mg/d and 800 IU/d, respectively) or an activated form of
vitamin D (eg, alfacalcidol 1 g/d or calcitriol 0.5 g/d)
should be offered to all patients receiving glucocorticoids to
restore normal calcium balance. Moreover bisphosphonates
are recommended to prevent bone loss in all men and
postmenopausal women in whom long-term treatment with
glucocorticoids is initiated at a 5-mg/d dose of prednisone
or equivalent and in men and postmenopausal women receiv-
ing long-term glucocorticoids in whom the bone mineral
density T score at either the lumbar spine or the hip is below
normal.18,19 On the contrary, proton-pump inhibitors are not
routinely indicated when corticosteroids are used without
NSAIDs.20
Moreover, corticosteroid therapy has been found to be an
independent risk factor for recurrences not only in acute
Figure. Event-free survival of patients treated with prednisone
1 mg · kg1 · d1 (thick line) vs those treated with lower doses
(dotted line). Adverse events included severe side effects, recur-
rences, cardiac tamponade, and constrictive pericarditis.
Table 3. Follow-Up Data of the Studied Population
Low Doses
(n49)
Prednisone
1 mg  kg1  d1
(n51) P
Prednisone, mg* 33.312.6 68.89.6 0.001
Colchicine, n (%) 40 (81.6) 41 (80.4) 0.920
Follow-up, mo 57.627.5 54.117.8 0.450
Severe side effects, n (%) 1 (2.0) 12 (23.5) 0.002
Minor side effects, n (%) 7 (14.3) 10 (19.6) 0.597
Recurrence, n (%) 16 (32.6) 33 (64.7) 0.002
Hospitalization, n (%) 4 (8.2) 16 (31.4) 0.005
Values are meanSD when appropriate. No cases of cardiac tamponade
and constriction were recorded in either group.
*Mean dose.
Table 4. Hazard Ratios for Severe Side Effects, Recurrences,
or Hospitalizations in the Cox Proportional-Hazards Model
Feature HR 95% CI P
Age 0.98 0.97–1.01 0.130
Female gender 1.23 0.68–2.19 0.487
Nonidiopathic cause 1.40 0.77–2.54 0.267
High doses of prednisone 3.61 1.96–6.63 0.001
HR indicates hazard ratio; CI, confidence interval.
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pericarditis (odds ratio, 4.30)13 but also for the first recur-
rence (odds ratio, 2.9 to 10.0)12,14 and after multiple recur-
rences (odds ratio, 6.7).21 A possible explanation is that
some recurrences may be provoked by acute or chronic
viral infections,2,22 and corticosteroids could promote viral
replication.13,23
Thus, NSAIDs should be the mainstay of therapy for acute
and recurrent pericarditis, and corticosteroids should be
considered only as a second-choice therapy in patients with
poor general conditions or in frequent crisis unresponsive to
NSAIDs as a last resort. In these cases, very low tapering only
after stable remission with symptom resolution and normal-
ization of C-reactive protein is the key to successful manage-
ment of the disease, similar to what is often done in
polymyalgia rheumatica. During tapering, colchicine should
always be considered, starting with low doses (eg, 0.5 mg, to
improve gastrointestinal tolerability).13–15 Growing evidence
shows that the drug may be effective in preventing recur-
rences, reducing the need for prolonged treatment with
steroids.14,15,21,23,24
Intrapericardial administration of corticosteroids has been
proposed as a means to minimize steroid-induced side ef-
fects,25,26 but there are technical considerations that may limit
the usefulness of intrapericardial therapy. If the patient
has small or no pericardial effusion, pericardioscopy or the
PerDUCER technique must be available to utilize this form of
treatment, and both remain investigational tools for most.
The present study shows that the use of low to moderate
doses of prednisone (0.2 to 0.5 mg · kg1 · d1) is efficacious
and may substantially reduce the risk of severe side effects
that may be life-threatening and often cause the early with-
drawal of therapy. Early withdrawal and quick tapering
resulting from side effects are common causes of recrudes-
cence of the disease, explaining a double recurrence rate in
patients treated with high doses of prednisone (see Table 3).
While awaiting future randomized controlled trials, we pro-
pose abandoning high-dose prednisone as an initial approach
to recurrent pericarditis unresponsive to optimal NSAID and
colchicine treatment.
Study Limitations
A first limitation of the study is the lack of a randomized
design and the retrospective design. Nevertheless, the 2
centers used a standardized different protocol for prednisone.
Moreover, a similar population was referred to the 2 centers,
and the 2 study groups were well balanced for relevant
clinical data such as origin, gender, and severity of the disease
at baseline (number of previous recurrences, previous cardiac
tamponade, pericardial effusion; see Table 2). We also
performed an adjustment for more evident potential con-
founders (age, female gender, and nonidiopathic origin).
Thus, we can reasonably exclude that more severe cases were
assigned to a specific treatment such as high-dose prednisone
while milder forms were assigned to low doses. A second
limitation is that a definitive diagnosis based on cytology,
immunohistochemistry, or pericardial, endomyocardial, or
epicardial biopsy is not available in all cases. A complete
diagnostic workup is clearly worthwhile and should be
available if possible before any treatment, particularly when
corticosteroids are adopted. In the ideal world, idiopathic
pericarditis would not exist. In the real world, in some cases
of acute or recurrent pericarditis, the cause has not been or
cannot be established. Because of the complexity of estab-
lishing whether the relapse is an autoimmune effect or the
result of reinfection or a new infection, many clinicians
treat these patients empirically, and they often resort to
corticosteroids.
Even with its limitations, our study challenges current
practice that is based on only 1 study of 12 patients10 and is
associated with an unacceptably high rate of severe side
effects. This study may serve as a basis for a future prospec-
tive randomized trial.
Conclusions
Corticosteroid therapy is a double-edged weapon in patients
with pericardial diseases; it may have specific but rare
indications (definite rheumatologic disease, presumed auto-
immune origin, intolerance or contraindications to aspirin or
NSAIDs, pregnancy), but it should be a last resort. High
doses have been recommended with only a single small
retrospective study supporting this use in recurrent pericardi-
tis, whereas lower doses usually are used to treat pericarditis
in autoimmune diseases. We observed that these doses
(prednisone 0.2 to 0.5 mg · kg1 · d1) were more effective
than higher doses in reducing recurrences and hospitaliza-
tions and induced considerably fewer side effects, so we
propose that these lower doses should be considered in
clinical practice. When corticosteroids are used, osteoporosis
prevention is recommended as a rule. It is anticipated that this
change in clinical practice will greatly decrease the burden of
corticosteroids side effects in pericarditis while maintaining
efficacy.
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CLINICAL PERSPECTIVE
The present observational study challenges the widespread practice of using high doses of prednisone or other
corticosteroids to treat pericarditis. Use of corticosteroids should be restricted in pericarditis, but when indicated, high
doses (prednisone 1.0 to 1.5 mg · kg1 · d1) have been recommended in reviews and in the European guidelines on the
management of pericardial diseases, although only a single small retrospective study supported high-dose use in recurrent
pericarditis. Lower doses usually are used to treat pericarditis in autoimmune diseases. In this nonrandomized observation,
it appeared that higher doses of prednisone (1.0 mg · kg1 · d1) for recurrent pericarditis were associated with more side
effects, recurrences, and hospitalizations (hazard ratio, 3.61; 95% confidence interval, 1.96 to 6.63) than lower doses
(prednisone 0.2 to 0.5 mg · kg1 · d1). It is important to search for a cause of recurrent pericarditis as diligently as possible,
with therapy directed at the specific cause. This observational study challenges the current practice of routine high-dose
corticosteroids for recurrent “idiopathic” pericarditis and should serve as the basis for a randomized trial.
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